| Auction | Auction results |
| Auction date | 2026-11-03 |
| Start date | 2026-11-04 |
| Maturity date | 2026-11-11 |
| Interest rate | 1.75 % |
| Offered volume, SEK bn | 470.0 |
| Total bid amount, SEK bn | 387.26 |
| Accepted volume, SEK bn | 387.26 |
| Number of bids | 15 |
| Percentage allotted, % | 100.00 |
Integrates BIO-key’s IAM, biometric authentication, and passwordless technologies into Cipher’s cybersecurity portfolio, with plans for international expansion
LISBON, Portugal and HOLMDEL, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global provider of Identity and Access Management (IAM) and biometric authentication solutions, today announced a technology integration with Cipher, Prosegur’s specialized cybersecurity division, bringing BIO-key’s identity security technologies into Cipher’s cybersecurity services and solutions portfolio.
The integration addresses the increasing convergence between cybersecurity, identity management, and access governance. As organizations adopt cloud services, digital platforms, and AI-driven technologies, ensuring that the right individual or authorized entity is accessing the right resource has become fundamental to enterprise security.
The initial launch will be in Portugal, leveraging the organizations’ complementary capabilities to address the growing demand for advanced identity protection, stronger authentication, and Zero Trust security. The companies plan to progressively expand the integration and commercial opportunities across international markets, creating a broader framework for collaboration.
Cipher, a Prosegur company, is a specialized cybersecurity provider with more than 20 years of experience, over 200 cybersecurity professionals, and operations across Spain, Portugal, the United States and Brazil. Through its network of six Cybersecurity Operations Centers and its managed cybersecurity services, Cipher supports organizations in strengthening their security posture, managing cyber risks, and protecting critical digital environments.
By incorporating BIO-key’s identity security technologies into its cybersecurity portfolio, Cipher will be able to extend its offering beyond traditional cybersecurity protection to address one of the most critical components of modern enterprise security: the identity of the individual accessing systems, applications, and sensitive information.
Bringing Identity Security into the Cybersecurity Ecosystem
The integration brings BIO-key’s comprehensive identity security capabilities into Cipher’s broader cybersecurity offering, providing additional capabilities for organizations seeking to strengthen authentication and identity protection.
The combined technology portfolio includes:
A Strategic Collaboration with International Ambitions
The initial implementation in Portugal provides a foundation for bringing together BIO-key’s identity security technologies and Cipher’s established cybersecurity capabilities and customer relationships.
Both organizations intend to explore opportunities to extend the integrated offering into additional markets where Cipher operates, leveraging Prosegur’s international presence and BIO-key’s global IAM capabilities.
This strategy reflects a broader industry evolution in which identity security is becoming an increasingly important component of comprehensive cybersecurity strategies. By integrating identity protection directly into cybersecurity services, the companies aim to help organizations address authentication vulnerabilities, reduce identity-related risks, and strengthen their overall security posture.
“Portugal is an important starting point for combining our complementary technologies and cybersecurity expertise to address evolving market needs,” said Luis Martins, Country Manager Portugal at Cipher, a Prosegur Company. “Organizations are recognizing that protecting their infrastructure is not enough if the identities accessing that infrastructure are not properly secured. By combining BIO-key’s advanced biometric authentication and IAM capabilities with Cipher’s cybersecurity expertise, we can deliver a more comprehensive approach to identity protection. We look to build a strong foundation in Portugal and then create opportunities to extend this integrated offering to customers across other markets.”
“We’re excited by the opportunity to connect Cipher/Prosegur’s established leadership and extensive footprint in physical security with the growing demand for enterprise cybersecurity,” said Alex Rocha, International Managing Director, BIO-key Inc. “They have built trusted relationships with more than 800 enterprise customers, and their integrated security operations center (iSOC) is a powerful example of how they bring together people, technology, data and intelligence to deliver integrated security services. Within this iSOC environment, BIO-key’s identity assurance can strengthen access to security platforms, operational systems and sensitive applications.
“As physical and digital security increasingly converge, organizations need to protect not only their facilities, people and assets, but also their digital identities, infrastructure and AI-driven operations. BIO-key can help extend Prosegur’s security proposition into this broader ecosystem. Together, we can help organizations move towards a more comprehensive security model in which physical security, cybersecurity and trusted digital identity work together.”
“This is an important strategic step in expanding BIO-key’s international technology ecosystem,” said Nicholas Prinz, International Channel Director, BIO-key Inc. “Cipher brings significant cybersecurity expertise, an established international presence, and a strong understanding of the security challenges faced by large organizations. Integrating BIO-key’s solutions into Cipher’s cybersecurity offering brings identity security closer to the center of enterprise cybersecurity strategies. We see considerable potential in Portugal and beyond. Our ambition is to forge an international initiative combining the strengths of both organizations. We look forward to a long-term relationship.”
About Cipher – A Prosegur Company (www.cipher.com) and (www.prosegur.com)
Cipher is a specialized cybersecurity division of Prosegur, a global security group operating in 36 countries with more than 180,000 employees. Cipher is dedicated to protecting organizations’ digital environments through advanced cybersecurity services, technology, and expertise. With more than 20 years of experience and a team of over 200 cybersecurity professionals operating across four countries, Cipher combines international capabilities with local market expertise.
Through its network of six Cybersecurity Operations Centers, Cipher delivers cybersecurity solutions and managed services designed to help organizations identify, manage, and reduce cyber risks. Its portfolio includes managed detection and response, cybersecurity operations, cyber intelligence, security assessments, penetration testing, Governance, Risk and Compliance (GRC), and its proprietary cybersecurity platforms.
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key International, Inc. (NASDAQ: BKYI) is a global provider of Identity and Access Management (IAM) and biometric authentication solutions. Its biometric-centric, multi-factor identity security technologies help organizations protect access to computers, applications, information, and high-value transactions for more than 40 million users worldwide.
BIO-key enables organizations to select authentication methods suited to their security, operational, and user requirements, including biometric, passwordless, tokenless, and phoneless authentication. Its cloud-hosted and on-premises PortalGuard® IAM platform supports Multi-Factor Authentication (MFA), Single Sign-On (SSO), and centralized access management. BIO-key’s Identity-Bound Biometrics technology provides an additional approach to identity assurance by binding authentication to the individual rather than relying exclusively on a device or credential.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “estimate,” “project,” “intend,” “expect,” “anticipate,” “believe,” and similar expressions. These statements are based on management’s current beliefs, assumptions, and information available to management and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied.
These risks and uncertainties include the factors described under “Risk Factors” in BIO-key’s Annual Report on Form 10-K for the year ended December 31, 2025, and in its other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as required by law, BIO-key undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, new information, or otherwise.
Engage with BIO-key
Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international
X – Corporate: @BIOkeyIntl
X – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800
Press Release
Eviden launches SMX, its new electromagnetic speed log for surface and underwater drones
Compact, discreet and engineered for the most demanding marine environments, SMX continuously measures speed through water with high accuracy. This mission-critical data helps optimize navigation and supports the autonomous operation of uncrewed naval platforms.
Paris, France – November 3, 2026 – Eviden, the Atos Group product brand leading in cybersecurity products, mission-critical systems and vision AI today announces through its BEN Marine brand, the launch of SMX. Rated to withstand pressures of up to 30 bar, equivalent to a depth of 300 meters, this new electromagnetic speed log features electronics fully integrated into the sensor, addressing naval forces’ stringent miniaturization requirements.
Designed for uncrewed surface vehicles (USVs) and uncrewed underwater vehicles (UUVs), including mine countermeasure vehicles, torpedoes, wet submersibles and missiles, SMX continuously measures speed through water with very high accuracy. This data is essential for monitoring a platform’s progress and accurately calculating the distance travelled and remaining distance. SMX is also suitable for civilian and oceanographic research vehicles, reflecting Eviden’s expertise in dual-use technologies.
SMX transmits speed data directly over a standardized NMEA interface, enabling data exchange between the vehicle’s various sensors and navigation system while ensuring synchronization. Calibration and diagnostics can be performed remotely, helping to maximize platform operational availability.
Building on the proven SM 2000, SMX uses electromagnetic technology that provides a key advantage for both surface and underwater operations, as it emits no acoustic signals. Compact and weighing less than 2 kg, it is also qualified to MIL-STD standards. Combining discretion, ruggedness and compactness, SMX is engineered to operate in particularly demanding maritime environments.
A qualified industrial facility for the design and production of advanced sovereign technologies
SMX is designed and manufactured in France. The sensor itself, which embodies BEN Marine’s core expertise, as well as final assembly and qualification, are carried out at Eviden’s mission-critical systems production facility in Aix-en-Provence. Eviden’s BEN Marine teams also provide through-life support for its electromagnetic speed logs, helping to maintain their operational availability throughout their service life.
Bernard Payer, head of Mission-Critical Systems at Eviden, Atos Group, said: “With the launch of SMX, Eviden is advancing a proven technology to meet the requirements of a new generation of autonomous maritime platforms. SMX demonstrates our ability to provide reliable navigation data in operational environments and to control the entire value chain, starting from the design stage.”
BEN Marine is Eviden’s brand dedicated to maritime navigation instruments for navies and professional fleets. Its portfolio includes electromagnetic speed logs, repeaters, flowmeters and compasses for naval vessels, fishing vessels, merchant ships and scientific research vessels. BEN Marine equipment is marketed through a worldwide distributor network. BEN Marine’s navigation systems continue the legacy of the Bianchetti navigation instrument workshop, founded in Marseille in 1822.
Eviden SMX loch © Eviden
***
About Eviden
Eviden is the Atos Group brand focused on cybersecurity products, mission-critical systems and vision AI. A trusted partner to public and private sector organizations, Eviden deploys advanced analytics capabilities and helps ensure the robustness, continuity and resilience of its customers’ operations. Leveraging more than 2,200 experts and 720 patents, Eviden helps protect people, data and critical infrastructures worldwide, at the convergence of intelligence, sovereignty and trust.
About Atos Group
Atos Group is a global leader in digital transformation with c. 53,000 employees and annual revenue of c. €7.2 billion, operating in 54 countries under two brands – Atos for services and Eviden for products and systems. European number one in cybersecurity and a leader in cloud, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is listed on Euronext Paris.
Press contact
Isabelle Grangé | isabelle.grange@atosgroup.com | +33 (0) 6 64 56 74 88
Attachment
Company announcement no. 44 – 26
03 November 2026
Transactions in connection with share buy-back program
On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 – 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules.
The purposes of the share buy-back programme are to meet obligations relating to acquisition of minority shareholders’ shares in NTG subsidiaries under the “Ring-the-Bell” concept, cover obligations arising under share-based incentive programmes, and potentially for other purposes such as payment in relation to potential M&A transactions.
During the period, NTG will purchase its own shares for an aggregate maximum amount of DKK 200,000,000, up to 1,250,000 shares (nominally DKK 25,000,000), corresponding to 5.52% of the current share capital of NTG.
The share buy-back programme will run from 5 March 2026 to 9 November 2026 at the latest, both days inclusive.
The following transactions have been made under the share buy-back program:
| Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| Accumulated, latest announcement | 839,922 | 190,277,226 | |
| 27 October 2026 | 3,000 | 334.7 | 1,004,003 |
| 28 October 2026 | 5,000 | 331.8 | 1,659,133 |
| 29 October 2026 | 5,639 | 330.4 | 1,862,962 |
| 30 October 2026 | 3,000 | 322.5 | 967,500 |
| 02 November 2026 | 3,000 | 330.5 | 991,500 |
| Accumulated under the program | 859,561 | 196,762,324 |
With the transactions stated above, NTG owns a total of 1,152,386 treasury shares, corresponding to 5.09% of the current share capital of NTG.
Details of each transaction are included as appendix.
Additional information
For additional information, please contact:
| Investor relations & Press: Sebastian Rosborg Head of Investor Relations & External communications |
+45 42 12 80 99 sebastian.rosborg@ntg.com ir@ntg.com | press@ntg.com |
Attachments
Nordic Fibreboard AS (register number 11421437, address Rääma 31, Pärnu 80044) Extraordinary General Meeting of shareholders was held today, on 3rd of November 2026 in Nordic Fibreboard AS office, at Rääma 31, Pärnu. The general meeting started at 10.00 and ended at 10:15.
According to the Articles of Association, the Company (hereinafter also referred to as the “Company”) has a total of 8,499,061 votes, of which 6,915,284 votes were represented at the meeting, constituting 81.365% of the share capital. Therefore, the General Meeting was competent to adopt resolutions on the items on the agenda. There were 2 Shareholders present.
The circle of shareholders entitled to participate in the Shareholders’ meeting was determined as of 27.10.2026 at the end of the working day of the Nasdaq CSD Estonian settlement system.
The notice to convene the meeting was disclosed on 12.10.2026 in the information system of the stock exchange and on Company website, and in the newspaper „Õhtuleht“ on 13.10.2026.
It was noted that the meeting had been convened in accordance with the requirements of the law and the Articles of Association.
Resolutions of the general meeting:
1. Amendment of the Articles of Association
Supervisory Board’s proposal: Amend the Company’s Articles of Association as follows:
To approve the new version of the Articles of Association as submitted to the extraordinary general meeting.
Voting results:
FOR – 6,915,284 votes, i.e. 100% of the votes represented at the meeting
AGAINST – 0
ABSTAINED – 0
DID NOT VOTE – 0
The resolution was adopted.
2. Conditional increase of Nordic Fibreboard AS share capital for the purpose of public offering of shares
Supervisory Board’s proposal: Conditionally increase the Company’s share capital by 625,000 euros, with the new conditional size of the Company’s share capital being 1,474,906.1 euros. The purpose of the conditional increase of the share capital is to arrange a public offering of the Company’s shares and their admission to trading on the secondary list of the Nasdaq Tallinn Stock Exchange. The public offering of shares will be organised by the Management Board of the Company. The Management Board of the Company is entitled to determine the terms of the public offering of shares that are not defined in this resolution. The number of the Company’s new shares will be decided, up to the conditional size of the Company’s share capital, and the Company’s new shares will be issued by the Management Board of the Company.
Only the existing shareholders of the Company are entitled to participate in the conditional increase of the share capital, and they are guaranteed a pre-emptive subscription right in proportion to the number of the Company’s shares held by them. The persons (shareholders) entitled to exercise the pre-emptive right will be determined as of the end of the business day of 5 November 2026 in the Nasdaq CSD settlement system, i.e. as of the date of publication of the stock exchange announcement of the public offering and of the information document.
The issue price of the shares is 0.4 euros per share, of which 0.1 euros is the book value of the share and 0.3 euros is the premium. The period for exercising the pre-emptive subscription right and for paying for the shares (the offering period) is from 6 November 2026 to 27 November 2026 (inclusive). The new shares will be paid for by monetary contributions.
The new shares will be allocated in accordance with the subscription orders, but not in excess of the pre-emptive subscription rights held by the respective person. To the extent exceeding that amount, the shares will be allocated among the subscribers in proportion to the pre-emptive rights held by each subscriber (but not in excess of the number of shares subscribed for by that person). If it appears that more shares have been subscribed for than are intended to be issued on the basis of this resolution, the subscribed shares will be allocated among the subscribers in proportion to the pre-emptive rights held by each subscriber. If the subscribed shares cannot be divided exactly among the subscribers, the final allocation of the subscribed shares among the subscribers will be decided by the Supervisory Board of the Company. If not all new shares have been subscribed for by the deadline set out in the resolution, the Management Board of the Company is entitled to extend the subscription period or to cancel the shares that have not been subscribed for during the subscription period.
The new shares to be issued will carry the right to dividends starting from the financial year 2026.
Voting results:
FOR – 6,915,284 votes, i.e. 100% of the votes represented at the meeting
AGAINST – 0
ABSTAINED – 0
DID NOT VOTE – 0
The resolution was adopted.
3. Admission of the new shares of Nordic Fibreboard AS to trading on the secondary list of the Nasdaq Tallinn Stock Exchange
Supervisory Board’s proposal: Apply for the admission of the Company’s new shares to trading on the secondary list of the Nasdaq Tallinn Stock Exchange.
Voting results:
FOR – 6,915,284 votes, i.e. 100% of the votes represented at the meeting
AGAINST – 0
ABSTAINED – 0
DID NOT VOTE – 0
The resolution was adopted.
Danel Hirbaum
CEO
Nordic Fibreboard AS
Phone: + 372 667 9200
E-mail: group@nordicfibreboard.com
| Bid date, 2026-11-03 | |
| Auction date | 2026-11-03 |
| Settlement date | 2026-11-04 |
| Maturity Date | 2026-11-11 |
| Nominal amount | 470 billion SEK |
| Interest rate | 1.75 % |
| Bid times | 09.30-10.00 (CET/CEST) on the Bid date |
| Bids are made to phone number | 08-696 69 70 |
| Confirmation of bids to e-mail | rbcert@riksbank.se |
| The lowest accepted bid volume | 1 million SEK |
| The highest accepted bid volume | 470 billion SEK |
| Allocation Time | 10.15 (CET/CEST) on the Bid date |
| Projected minimum liquidity surplus during the term | 470 billion SEK |
| Expected excess liquidity at full allotment | 0 billion SEK |
Stockholm, 2026-11-03
HSINCHU, Taiwan, Nov. 03, 2026 (GLOBE NEWSWIRE) — Faraday Technology Corporation (TWSE: 3035), a leading ASIC design service and IP provider, today announced an enhanced 10/100 Ethernet PHY IP solution supporting EtherCAT on UMC processes, addressing the growing demand for real-time communication and synchronized motion control in AI-powered manufacturing, industrial automation, and humanoid robotics. The pre-validated IP supports EtherCAT transmission time of less than 100 microseconds and synchronization accuracy of less than 0.1 microseconds using EtherCAT Distributed Clocks (DC), while having passed rigorous ETG.7000 Conformance and IEC 61000-4 testing to help streamline customers’ ASIC development.
Built on a DSP-based architecture combined with robust analog design, the Ethernet PHY IP provides enhanced noise immunity and reliable operation under severe electrical disturbances. The PHY IP has passed EtherCAT device compliance and network interoperability testing based on the ETG.7000 Conformance Test Specification, as well as key IEC 61000-4 electromagnetic compatibility (EMC) tests covering ESD, radiated RF, EFT/burst, surge, and conducted RF disturbances. Its robustness was further demonstrated through an EFT/burst immunity test lasting one hour or longer, during which solenoid valves generated high-frequency EFT/burst pulses to verify hardware protection and communication integrity. IP-level pre-validation helps reduce system-level design and verification efforts, as well as development risks.
“Real-time connectivity and robust noise immunity are essential for next-generation industrial systems, particularly as AI is increasingly integrated into manufacturing and physical machines,” said Flash Lin, COO of Faraday Technology. “By integrating EtherCAT compliance and EMC validation at the IP level, our Ethernet PHY IP helps customers simplify system development and reduce costly re-certification risks. Moving forward, Faraday will continue expanding its Ethernet IP portfolio to support industrial AI, software-defined vehicles, and humanoid robotics, including 10/100/1000BASE-T1 and Single Pair Ethernet (SPE) solutions.”
About Faraday Technology Corporation
Faraday Technology Corporation (TWSE: 3035) is dedicated to the mission of benefiting humanity and upholding sustainable values in every IC it handles. The company offers a comprehensive range of ASIC solutions, including total 3DIC packaging, Neoverse CSS design, FPGA-Go-ASIC, and design implementation services. Furthermore, its extensive silicon IP portfolio encompasses a wide array of offerings, such as I/O, Cell Library, Memory Compiler, ARM-compliant CPUs, LPDDR4/4X, DDR4/3, MIPI D-PHY, V-by-One, USB 3.1/2.0, 10/100 Ethernet, Giga Ethernet, SATA3/2, PCIe Gen4/3, and SerDes. For further details, visit www.faraday-tech.com or follow Faraday on LinkedIn.
CONTACT: Press Contact: Faraday Tech, Evan Ke, +886 3 578 7888 ext. 88689, media@faraday-tech.com
AB Akola Group and its subsidiaries (the Group) plan to invest EUR 52 million during the 2026/2027 financial year. The largest share of investment will go towards expanding and modernising Food Production. The Group also plans to acquire a grain elevator, expand storage infrastructure and introduce solutions to automate farm operations.
“Our largest investments are in Food Production, including new production lines and the modernisation of existing processes. We aim to produce more higher value-added products and manage costs more efficiently to improve profitability and returns on investment,” says Mažvydas Šileika, Member of the Board and Deputy CEO for Finance and Investments at AB Akola Group.
This financial year’s plans continue the Group’s ongoing investment programme. Over the past five financial years, Akola Group has invested EUR 212 million in its businesses, including EUR 69 million in the 2024/2025 financial year and EUR 43 million in 2025/2026.
Largest investments to expand Food Production
A total of EUR 38 million is planned to be invested in the Food Production segment during the current financial year, which began on 1 July 2026. The main investments will focus on installing an additional chicken parts cooking line and modernising the existing poultry evisceration line with the most advanced equipment of its kind in Europe.
This amount also includes investments in the expansion and modernisation of Vilniaus Paukštynas hatchery, upgrades to water supply infrastructure, and other poultry business projects.
EUR 6 million is earmarked for the expansion and modernisation of storage and milling infrastructure at Kauno grūdai, as well as preparatory work for new projects. These investments are included in the overall investment plan for the Food Production segment.
By increasing the share of Food Production in its business portfolio, the Group aims to strengthen long-term profitability and reduce the sensitivity of its results to short-term commodity market fluctuations.
New grain elevator to strengthen the grain collection network
The Group plans to invest EUR 9 million in the Partners for Farmers segment. The largest portion, EUR 4.5 million, is earmarked for the acquisition of a grain elevator. The project aims to strengthen grain collection and storage infrastructure and the Group’s position in the commodity supply chain.
Other investments in the segment will include the expansion of seed and fertiliser storage infrastructure in Latvia and the implementation of a yard management system.
Greater automation on farms
The Group plans to invest EUR 5 million in the Farming segment. Planned investments include installing robotic milking systems, upgrading feed storage and livestock farming infrastructure, and purchasing agricultural machinery and land.
These projects aim to automate some day-to-day dairy farming tasks, improve the efficiency of feed preparation and storage, and upgrade assets needed for farm operations.
“Farm automation and machinery upgrades help us organise day-to-day operations more efficiently. When making investment decisions, we assess the operational benefits of each solution and whether it will deliver the expected return on capital,” says M. Šileika.
The figures presented reflect the investment plan for the 2026/2027 financial year. Actual investment amounts and implementation schedules may be revised as projects progress.
SERSTECH GROUP, 1 JULY – 30 SEPTEMBER 2026
SERSTECH GROUP, 1 JANUARY – 30 SEPTEMBER 2026
Message from the CEO
Serstech delivered a strong third quarter. Revenue reached 18.5 MSEK, and we recorded a EBITDA of 2.4 MSEK. Order intake in the quarter was the second highest in the company’s history. In September, we also shipped more products in a single month than ever before.
During the quarter, we have doubled our in-house production capacity, which now represents a sales value of more than 6 MSEK per month. As a result, a substantial share of our deliveries in 2027 is expected to be produced in-house. This will support continued gross margin improvement, alongside our ongoing cost-of-goods sold reduction activities in R&D.
A shortage of electronic components is beginning to affect the market, resulting in price increases. We built inventory ahead of time, which has left inventory levels relatively high and weakened our cash position. Our inventory of components enables us to support sales and deliveries the coming quarters. We expect some minor production disruptions, but no major impact. We are currently placing component orders for delivery in Q2 2027 due to the extended delivery times.
Our cash balance is currently low, partly because we have already paid production costs to a larger extent for the larger orders delivered in September and October. The invoices from these deliveries and several smaller ones, totaling approximately 30 MSEK, are expected to be paid in November, December and January.
Oil prices remain a risk factor. A further increase in the oil prices could weaken some of our Asian customers’ ability to invest in new technology and lead to delays in ongoing business opportunities. Security and defense equipment remains a priority for most of our target countries, and we currently do not expect any cancellations of the coming tenders.
The 2027 budget process is under way. We expect to reduce both sales and R&D fixed costs next year compared with 2026, while continuing to improve gross margins through in-house production and lower overall production costs.
Pipeline growth was weak in 2025 amid uncertainty around tariffs. Since early summer this year, however, activity has moved back towards normal levels, and our pipeline is now at a record high. We expect a strong fourth-quarter order intake, giving us a solid foundation for continued growth and improved profitability in 2027.
Stefan Sandor, CEO
November 2026
For further information, please contact:
Stefan Sandor,
CEO, Serstech AB
Phone: +46 739 606 067
Email: ss@serstech.com
or
Arve Nilsson,
Chairman of the Board, Serstech AB
Phone: +45 40 35 82 65
Email: arve.nilsson@serstech.com
or visit: www.serstech.com
This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 08:45 CET on November 03, 2026.
Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG).
About Serstech
Serstech delivers solutions for chemical identification and has customers around the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. Serstech’s head office is in Sweden and all production is done in Sweden.
Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at www.serstech.com
Attachment
GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12
Berlin, Germany, November 3, 2026, 08.00 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, announces that the clinical and translational team of the GLORIA study1 have received the Award of German University Medicine 2026. It is awarded to one team each year by the German Association of Medical Faculties (MFT) and the Association of German University Hospitals (VUD), which announced the award on October 22, 2026.2
Background of the Prize
The German University Medicine Prize recognizes outstanding team achievements in university medical research, in particular innovation, the translation of research results into patient care, and their societal relevance. MFT and VUD represent the 40 medical faculties and 37 university hospitals in Germany.
The awarded GLORIA trial team comprises specialists in radiation oncology, neuro-oncology, neurosurgery, neuroradiology and neuropathology at the university medical centers of Bonn, Essen, Leipzig, Mannheim, Münster and Tübingen. Clinical leadership of the study lies with Dr. Frank Giordano (Mannheim); translational leadership lies with Dr. Julian Layer (Bonn). The prize ceremony will take place on November 24, 2026 in Berlin.
Scientific Rationale and Results Cited by the Awarding Bodies
A key mechanism of glioblastoma recurrence is the rapid re-establishment of the tumor’s blood supply after irradiation. Tumors use chemokines such as CXCL12 to rebuild their blood supply and to evade immune attack. NOX-A12 is designed to neutralize CXCL12.
According to MFT and VUD, observations from the GLORIA trial were further investigated to reveal a tumor escape mechanism. This discovery led the team to pursue a novel treatment approach that simultaneously inhibits two different pathways employed by tumors to restore blood supply. In an expansion cohort of six patients, NOX-A12 and radiotherapy were therefore combined with the anti-VEGF antibody bevacizumab to address both pathways. The combination treatment was well tolerated, and a median overall survival of 19.9 months was reported. MFT and VUD describe these results as first promising indications of the benefit of the approach. The results have been published in two articles in Nature Communications3.
“We congratulate Dr. Giordano, Dr. Layer and the entire GLORIA team on this well-deserved recognition. The German University Medicine Prize was awarded by for the way the team connected clinical observations with translational research. We regard this as a strong external validation of the scientific rationale behind TME’s development of NOX-A12 in glioblastoma: preventing the tumor from rebuilding its blood supply after radiotherapy. We look forward to building on this work in the planned randomized extension of the GLORIA study with TMS Co. Ltd. This prestigious prize and the publications in Nature Communications validate the quality of the program, and I am therefore convinced that there is enormous value to be unlocked for investors,” said Diede van den Ouden, CEO of TME Pharma.
For more information, please contact:
TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com
www.tmepharma.com
About TME Pharma
TME Pharma is a biotechnology company with two assets with potential to be developed into novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The Company’s two lead assets are:
The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:
About the GLORIA Study
The GLORIA (NCT04121455) ‘ready to go’-study is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy and bevacizumab in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).
About the OPTIMUS Study
OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.
About the Preis der Deutschen Hochschulmedizin
The Preis der Deutschen Hochschulmedizin (German University Medicine Prize) is awarded by the German Association of Medical Faculties (MFT) and the Association of German University Hospitals (VUD), whose umbrella organization is Deutsche Hochschulmedizin e.V. It honors outstanding team achievements in university medical research, in particular innovation and the translation of research results into patient care. Preis der Deutschen Hochschulmedizin – Deutsche Hochschulmedizin e.V.
Further information can be found at: www.tmepharma.com.
1 NCT04121455 – GLORIA study on clinicaltrials.gov
2Press release of MFT and VUD, “Neuer Ansatz gegen aggressive Gehirntumore: GLORIA-Team erhält Preis der Deutschen Hochschulmedizin 2026,” Berlin, October 22, 2026.
3 Giordano et al 2024, Nature Comm 15:4210, Giordano 2024
Giordano et al. 2026, Nature Comm 17:3405, Giordano 2026
Attachment
